A heterozygous pathogenic variant means you carry one altered copy and one normal copy of a particular gene, and the altered copy has been judged by clinical laboratories to be disease-causing. Whether that single altered copy actually makes you sick depends heavily on which gene is involved and how the associated condition is inherited. For some conditions, one pathogenic copy is enough to cause problems; for others, you are simply a carrier with no symptoms at all. The term sounds alarming on a genetic report, but its real-world consequences vary enormously.
What “Pathogenic” Means on a Genetic Report
Genetic testing laboratories classify every variant they find on a five-tier scale: pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, or benign. These categories come from guidelines established by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Each variant is weighed against multiple lines of evidence, including how rare it is in the general population, whether it disrupts the protein in a predictable way, and whether it has been seen in other patients with the same disease. The evidence is scored and combined to land on one of the five tiers. If a variant does not clearly land in the pathogenic or benign direction, it defaults to “uncertain significance.”1PubMed Central. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
So “pathogenic” is not a guess. It means substantial evidence supports the conclusion that this variant causes disease. But that classification describes the variant itself in isolation. It does not automatically tell you what will happen in your body, because the next critical question is whether the condition linked to that gene requires one or two damaged copies to manifest.
How the Inheritance Pattern Changes Everything
The single most important factor in interpreting a heterozygous pathogenic variant is whether the associated condition follows dominant or recessive inheritance. In a dominant condition, a pathogenic change in just one copy of the gene can cause disease. In a recessive condition, both copies need to be altered before the condition typically develops. This distinction is not a minor footnote; it is the difference between being told you have a health risk and being told you are an unaffected carrier.
Pathogenic variants can disrupt a gene’s function through several mechanisms. They can simply knock out the gene’s protein production, creating a loss of function. In dominant conditions, this sometimes happens through haploinsufficiency, meaning the single working copy cannot produce enough protein to keep things running normally. Other dominant variants act through a “dominant-negative” mechanism, where the faulty protein actively interferes with the normal protein, or through a “gain of function,” where the altered protein acquires a new, harmful activity.2PubMed. Dominant negative variants and cotranslational assembly of macromolecular complexes The mechanism matters because it shapes both the severity and the treatment approach.
When You Are a Carrier and Likely Unaffected
If your heterozygous pathogenic variant sits in a gene linked to an autosomal recessive condition, you are generally a carrier. Carriers of recessive conditions typically show no symptoms because the one functional copy of the gene produces enough protein to do the job.3PubMed Central. The Spectrum of the Heterozygous Effect in Biallelic Mendelian Diseases-The Symptomatic Heterozygote Issue Cystic fibrosis is the classic example: millions of people carry one pathogenic variant in the CFTR gene and live completely healthy lives. Only when someone inherits pathogenic variants from both parents does the disease appear.
That said, the word “seem” does real work in the research here. There is growing awareness that some carriers of recessive conditions experience subtle effects. A carrier of a sickle cell variant, for instance, might have very mild symptoms under extreme physical stress. These edge cases are still being studied, and for the vast majority of recessive genes, heterozygous carriers can expect to be asymptomatic. The main implication for carriers is reproductive: if your partner also carries a pathogenic variant in the same gene, each pregnancy has a one-in-four chance of producing a child with the condition.
When One Copy Is Enough
For dominant conditions, a single heterozygous pathogenic variant can directly cause disease. Conditions like Marfan syndrome, many forms of hereditary cancer susceptibility, and certain cardiac rhythm disorders fall into this category. If your report identifies a heterozygous pathogenic variant in a gene associated with a dominant condition, your genetic counselor or physician will typically recommend surveillance, preventive measures, or both.
De novo variants are worth understanding in this context. These are pathogenic variants that arise freshly in you and were not inherited from either parent. They are especially common in conditions involving neurodevelopment. Researchers have documented cases where a single new heterozygous mutation in a gene like DYRK1A causes a recognizable syndrome of developmental delay through loss of the protein’s function.4PubMed Central. A novel de novo heterozygous DYRK1A mutation causes complete loss of DYRK1A function and developmental delay Similar de novo heterozygous mutations in DNM1L have been linked to developmental delay with neurological features.5PubMed Central. A Novel de novo Mutation in DNM1L Presenting With Developmental Delay, Ataxia, and Peripheral Neuropathy If you carry a de novo dominant variant, the practical upshot is that your parents likely do not carry it and are not at risk, but you could pass it on to your children with a 50 percent chance per pregnancy.
Penetrance and Why Having the Variant Does Not Guarantee Disease
Even for dominant conditions, carrying a heterozygous pathogenic variant does not always mean you will develop the associated disease. The concept that trips people up here is penetrance: the proportion of people with a given variant who actually show symptoms. Some variants are fully penetrant, meaning virtually everyone who carries them will eventually develop the condition. Others show incomplete penetrance, meaning a real fraction of carriers remain unaffected throughout their lives.
The reasons for incomplete penetrance are still being untangled. Researchers point to the specific mutation itself, the person’s sex, age, epigenetic modifications, environmental exposures, and the influence of other genetic variants elsewhere in the genome.6PubMed Central. Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease In some cases, full penetrance seems to require the presence of additional genetic variants at other loci, meaning the pathogenic variant alone is necessary but not sufficient. The takeaway for someone reading their own report is that a heterozygous pathogenic variant in a dominant gene should be taken seriously, but it is not a certainty of illness. It is a risk factor whose magnitude depends on the gene, the specific variant, and your broader biology.
Variable expressivity is a related but distinct phenomenon. Two people can carry the exact same variant, both develop the condition, and yet look very different clinically. One person with a variant in the gene causing neurofibromatosis might have a few subtle skin findings, while another has tumors along major nerves. Factors thought to drive this variability include common genetic variants in the background, regulatory region changes, epigenetics, and lifestyle.7PubMed Central. Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts
Your Broader Genetic Background Shifts Risk Substantially
One of the more striking findings in recent years is that a person’s polygenic background, the cumulative effect of thousands of common genetic variants scattered across the genome, can dramatically modify the risk conferred by a single pathogenic variant. This is not a minor fine-tuning effect; the numbers are large enough to change clinical decisions.
For coronary artery disease, researchers found that among carriers of monogenic risk variants, the probability of developing disease by age 75 ranged from about 5 percent for those with the lowest polygenic risk scores to roughly 78 percent for those with the highest.8Nature Communications. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions That is a fifteen-fold spread among people carrying the same type of monogenic variant. Similar patterns have been observed in kidney disease, where carriers of qualifying variants in genes associated with autosomal dominant polycystic kidney disease showed risk gradients that differed dramatically depending on their polygenic risk score.9PubMed Central. Polygenic risk alters the penetrance of monogenic kidney disease In cardiomyopathies, carriers of rare pathogenic variants in the top 20 percent of polygenic risk had several times the disease risk of those in the bottom 20 percent.10Human Genetics and Genomics Advances. Refined genetic architecture of hypertrophic and dilated cardiomyopathies with common genetic modifiers and rare pathogenic variants
What this means in practice is that two people looking at identical lab reports showing the same heterozygous pathogenic variant may face very different actual risks. Polygenic risk scores are not yet standard on most clinical genetic reports, but they are increasingly being integrated into research settings, and this is one area where clinical genetics is evolving rapidly.
Cancer Genes and the Two-Hit Model
Hereditary cancer susceptibility is one of the most common reasons someone discovers they carry a heterozygous pathogenic variant. Genes like BRCA1, BRCA2, and TP53 are tumor suppressors. Under the “two-hit” model first proposed decades ago, an inherited pathogenic variant in one copy of a tumor suppressor gene acts as the first hit. Cancer develops when the remaining normal copy of that gene is knocked out by a second, somatic mutation that happens in a single cell during a person’s lifetime.11Cancer Prevention Research. One-Hit Effects and Cancer
This is why carriers of heterozygous BRCA variants do not have cancer from birth. They have one functioning copy doing its job. But because every cell in their body already has one copy disabled, the odds that a second hit will occur in a breast or ovarian cell over a lifetime are considerably elevated compared to someone who would need two independent somatic mutations in the same cell. The practical response is increased screening, risk-reducing medications, and in some cases preventive surgery. The two-hit framework also explains why the cancers that develop in these individuals tend to appear earlier in life than sporadic cancers in the general population.
Which Parent the Variant Came From Can Matter
For most genes, it does not matter whether the pathogenic variant was inherited from your mother or your father. But in a subset of genes that are subject to genomic imprinting, the parent of origin changes the picture considerably. Imprinting is a process where certain genes are chemically tagged so that only the copy from one parent is active. If the pathogenic variant happens to sit on the active copy, it causes problems. If it sits on the silenced copy, it may have no effect at all.12PubMed Central. Genomic imprinting and parent-of-origin effects on complex traits
Recent research has shown that parent of origin has practical clinical consequences even beyond classic imprinting disorders. In retinoblastoma, a childhood eye cancer, researchers using long-read sequencing found that children carrying disease-causing variants on the paternally inherited allele had more advanced cancer at diagnosis and a significantly higher risk of chemotherapy failure compared to those carrying the variant on the maternal allele.13PubMed Central. Prognostic importance of direct assignment of parent of origin via long-read genome and epigenome sequencing in retinoblastoma Standard genetic testing does not always determine which parent contributed the variant, but as sequencing technology advances, parent-of-origin assignment is becoming more feasible and clinically relevant.
Compound Heterozygosity and the Recessive Twist
Sometimes a person carries two different pathogenic variants in the same recessive gene, one inherited from each parent. This is called compound heterozygosity, and it is functionally equivalent to having a recessive condition even though the two variants are not identical. Each parent is heterozygous for one of the variants and is individually unaffected, but the child who inherits both ends up with no working copies of the gene.14PubMed Central. Compound heterozygosity of predicted loss-of-function DES variants in a family with recessive desminopathy
This matters practically because a genetic test might initially flag a single heterozygous pathogenic variant in a recessive gene and call you a carrier. If a second, different pathogenic variant in the same gene is discovered later, or if the initial test only sequenced part of the gene, the interpretation shifts from “carrier” to “affected.” Comprehensive testing that examines the full gene, along with parental testing to confirm whether two variants are on different chromosomes (in trans), is the way to sort this out.
Variants Can Be Reclassified Over Time
Variant classification is not permanent. As more patients are tested and more functional data accumulate, laboratories revisit their assessments. In one review of patients tested for BRCA1 and BRCA2, updates to genetic databases and family studies led to 13 variants of uncertain significance being reclassified as pathogenic or likely pathogenic, affecting about 7 percent of the patients. Another 8 variants were downgraded to “likely benign,” which changed the risk assessment for about 15 percent of patients and their families.15PubMed Central. How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?
Reclassification flows in both directions: some variants are upgraded to pathogenic, and some are downgraded to benign. Population databases like gnomAD play a role here. If a variant once thought to be rare turns out to be relatively common in a specific ancestral population, that frequency information pushes against a pathogenic classification.16PubMed Central. Variant interpretation using population databases: Lessons from gnomAD If you received genetic testing more than a few years ago, it is worth asking your genetic counselor whether any of your variants have been reclassified.
What This Means for Your Family
A heterozygous pathogenic variant in your DNA has implications beyond your own health. If the variant was inherited (rather than de novo), at least one of your parents carries it too. Your siblings each had a 50 percent chance of inheriting the same variant. And your children each have a 50 percent chance of receiving it from you. This cascade of risk is why genetic counselors often recommend “cascade testing,” the process of systematically offering genetic testing to biological relatives after a pathogenic variant is identified in one family member.
The value of cascade testing depends on whether the variant is actionable. For hereditary cancers, identifying carriers among relatives can lead to earlier screening and prevention that genuinely saves lives. For conditions like familial hypercholesterolemia, cascade testing can identify relatives who would benefit from early statin therapy. Beyond medical management, carrier information is relevant for reproductive planning: relatives of childbearing age may want to know their carrier status before starting a family, particularly for recessive conditions.17PubMed Central. Cascade health service use in family members following genetic testing in children: a scoping literature review
Mosaicism and Low-Level Variants
Not all heterozygous pathogenic variants are straightforward germline findings. Sometimes a variant is present only in a fraction of cells, a state called somatic mosaicism. This happens when the mutation arose after fertilization, during early embryonic development, so only the cells descended from the mutated cell carry it.18PubMed Central. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis Mosaic variants can show up at low allele frequencies on genetic testing, sometimes as low as 5 to 15 percent rather than the expected 50 percent for a true heterozygous germline variant.
Mosaicism complicates interpretation in several ways. A mosaic variant may cause milder disease because not all tissues are affected. It may be harder to detect, potentially being missed entirely if the affected tissue was not sampled. And it changes the recurrence risk for children: a person with a mosaic variant has a lower but non-zero chance of passing it to offspring, compared to the standard 50 percent for a germline heterozygous variant. When a genetic report shows a pathogenic variant at an unexpectedly low allele fraction, further testing is usually warranted to distinguish true germline heterozygosity from mosaicism and from clonal hematopoiesis, an age-related expansion of blood cells carrying acquired mutations.
Heterozygote Advantage in Evolutionary Context
The fact that some clearly pathogenic variants persist at surprisingly high frequencies in certain populations is not an accident. Evolutionary biology offers an explanation through heterozygote advantage: the phenomenon where carrying one copy of a harmful variant confers a survival benefit, even though two copies cause disease. The sickle cell trait and malaria resistance is the most famous example, but the principle extends broadly. Natural selection has shaped the prevalence of certain alleles as human populations encountered distinct pathogens in different environments.19PubMed Central. Natural selection and infectious disease in human populations
Modeling work has shown that heterozygote advantage can maintain extraordinary diversity at immune-system genes, potentially sustaining over 100 alleles at a single locus if the selective pressures are strong enough.20PubMed Central. Heterozygote advantage can explain the extraordinary diversity of immune genes This is a reminder that “pathogenic” is context-dependent. A variant that causes severe anemia in homozygotes may be actively beneficial in heterozygotes in a malaria-endemic region. Genetic testing reports do not account for these evolutionary nuances; they classify the variant based on its potential to cause disease, not its possible historical benefits.